Net Revenues: $719.9 million for the full year. BAQSIMI Revenue: $185.4 million, up 12% year over year. Primatene Mist Revenue: $108.7 million, up 7% year over year. Iron Sucrose Revenue: $4.4 million ...

Shares of United Therapeutics climbed after the company said it planned to release a new soft mist inhaler to treat certain lung diseases next year. The stock rose 9%, to $515.94, midday Wednesday and ...

Management explicitly guided to lower gross margins in 2026, attributing the pressure to "continued pricing pressure on glucagon, epinephrine, and phytonadione, which are high-margin products," and ...

Investing.com - Needham lowered its price target on Amphastar Pharmaceuticals (NASDAQ:AMPH) to $30 from $34 while maintaining a Buy rating following the company’s fourth-quarter results. Despite the ...

Amphastar Pharmaceuticals reported its fourth-quarter 2025 earnings, revealing a significant miss in both earnings per share (EPS) and revenue compared to analyst forecasts. The company’s EPS came in ...

Dan Dischner: Thank you, Paul. Good afternoon, everyone, and thank you for joining Amphastar Pharmaceuticals, Inc.'s fourth quarter 2025 earnings call. 2025 was a pivotal year for the company, ...

Changes in product revenues, net as compared to the fourth quarter of the prior year were primarily driven by: BAQSIMI ® sales increased primarily due to an increase in unit volumes, as a result of ...

Greetings, and welcome to the Amphastar Pharmaceuticals Fourth Quarter Earnings call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not ...

Amphastar Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $0.73 EPS, expectations were $0.97. Operator: Greetings, and welcome to the Amphastar Pharmaceuticals Fourth Quarter ...

On February 26, 2026, H.C. Wainwright raised the price target on United Therapeutics Corporation (NASDAQ:UTHR) from $525 to $600 while maintaining a Buy rating. The company has announced that it is ...